BiotechTube

Varenicline + Nicotine patch

ApprovedWithdrawn
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Tobacco Use Cessation

Conditions

Tobacco Use Cessation, Psychiatric Disorders

Trial Timeline

Jan 1, 2019 → Apr 1, 2020

NCT ID
NCT03809897

About Varenicline + Nicotine patch

Varenicline + Nicotine patch is a approved stage product being developed by Rafael Holdings for Tobacco Use Cessation. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03809897. Target conditions include Tobacco Use Cessation, Psychiatric Disorders.

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03809897ApprovedWithdrawn

Competing Products

20 competing products in Tobacco Use Cessation

See all competitors
ProductCompanyStageHype Score
Nicotine + Nicotine + NicotineJohnson & JohnsonPre-clinical
23
Nicotine Gum + Nicotine PatchJohnson & JohnsonApproved
85
Nicotine Medicated Gum + 4 mg Nicotine Gum + 2 mg Nicotine Gum + 4 mg Nicotine LozengeJohnson & JohnsonPre-clinical
23
Nicotine + NicotineJohnson & JohnsonPre-clinical
23
Nicotine + NicotineJohnson & JohnsonPhase 1
33
Nicotine + Nicotine + NicotineJohnson & JohnsonPhase 1
33
NicotineJohnson & JohnsonPre-clinical
23
6 mg Experimental nicotine gum + 4 mg Nicotine Gum/ + 2 mg Nicotine GumJohnson & JohnsonPre-clinical
23
Nicorette Strongmint lozenge 4 mg + Niquitin MiniMint lozenge 4 mgJohnson & JohnsonPhase 1
33
Oral Nicotine + Nicotine Lozenge + Nicotine gumJohnson & JohnsonPre-clinical
23
Nicotine + Nicotine GumJohnson & JohnsonPre-clinical
23
Code STD + Code STE + Nicorette MicrotabJohnson & JohnsonPre-clinical
23
Experimental Nicotine Replacement Therapy (NRT) 2 mg + Experimental Nicotine Replacement Therapy (NRT) + Marketed Nicotine Lozenge + Marketed Nicotine LozengeJohnson & JohnsonPre-clinical
23
Nicotine + Nicorette® (Nicotine Gum)Johnson & JohnsonPre-clinical
23
Nicotine + Nicotine GumJohnson & JohnsonPre-clinical
23
Nicotine Sublingual Tablet Mint (NSTM) + Marketed Nicotine TabletJohnson & JohnsonPre-clinical
23
NicotineJohnson & JohnsonPre-clinical
23
Nicotine Spray + PlaceboJohnson & JohnsonPhase 3
77
Placebo + NicotineJohnson & JohnsonPhase 3
77
Bupropion SRJohnson & JohnsonApproved
85

Other Products from Rafael Holdings

Polyethylene glycol 4000 + Macrogol 3350 plus ascorbic acidApproved
77
inhaled corticosteroid plus LABA plus oral corticosteroidApproved
77
IV trivalent saccharose hydroxide ferrous + Oral ferrous fumarate + Oral and intravenous PlaceboApproved
77
Insulin + insulinApproved
77
Tacrolimus with rapid steroid withdrawal + Tacrolimus with steroids minimization + CsA with steroid minimizationApproved
77